Table 3. Biochemical parameters of the patients at baseline and the end of the study.
| Variable | Placebo (n=49) | NAM (n=49) | P‡ | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 52nd week | P* | Baseline | 52nd week | P† | |||
| Phosphorus (mmol/L) | 2.48±0.50 | 2.26± 0.66 | 0.072 | 2.49±0.50 | 2.04±0.58 | 0.000 | 0.032 | |
| Total calcium (mmol/L) | 2.19±0.21 | 2.32±0.25 | 0.006 | 2.18±0.26 | 2.30±0.24 | 0.024 | 0.681 | |
| Intact PTH (pmol/L) | 239.45±70.38 | 226.25±50.30 | 0.288 | 240.27±71.63 | 227.02±74.35 | 0.371 | 0.952 | |
| 25-OH vitamin D (ng/mL) | 26.14±4.87 | 24.98±5.19 | 0.257 | 27.19±4.48 | 23.59±5.41 | 0.001 | 0.199 | |
| Albumin (g/L) | 42.04±4.17 | 41.24±3.25 | 0.295 | 42.91±3.95 | 42.10±3.80 | 0.307 | 0.232 | |
| AST (IU/L) | 9 [7, 12.5] | 9 [7.5, 12] | 0.963 | 10 [8, 14.5] | 10 [6.5, 12] | 0.285 | 0.781 | |
| ALT (IU/L) | 7 [6, 12] | 7 [5, 12] | 0.639 | 8 [6, 11] | 8 [5, 11] | 0.960 | 0.901 | |
| C-reactive protein (mg/L) | 5.5±1.8 | 5.6±1.9 | 0.727 | 5.6 ±1.6 | 5.7±1.5 | 0.925 | 0.909 | |
| Hemoglobin (g/dL) | 108.02±14.42 | 108.88±12.50 | 0.754 | 108.98±11.10 | 112.45±13.25 | 0.163 | 0.173 | |
| Platelet count (103/mm3) | 201±50 | 197±48 | 0.716 | 198±63 | 184±57 | 0.249 | 0.230 | |
| Triglycerides (mmol/L) | 1.92±0.73 | 1.97±0.87 | 0.757 | 1.94±0.89 | 2.01±0.82 | 0.682 | 0.800 | |
| HDL cholesterol (mmol/L) | 1.03±0.26 | 1.01±0.25 | 0.638 | 1.02± 0.33 | 1.15±0.28 | 0.044 | 0.009 | |
| LDL cholesterol (mmol/L) | 2.71±0.82 | 2.78±0.73 | 0.666 | 2.72±0.80 | 2.75±0.65 | 0.859 | 0.810 | |
Data are reported as the mean ± SD or (for variables with a non-Gaussian distribution) the median [interquartile range]. *, the 52nd week versus the baseline in the placebo group; †, the 52nd week versus the baseline in the NAM group; ‡, the placebo group versus the NAM group on the 52nd week. NAM, nicotinamide; AST, aspartate aminotransferase; ALT, alanine aminotransferase.